Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02289716 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT02289716 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 41 participants.
The verdict
NCT02289716, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not adequately controlled by current pain therapy.
Interventions
- DRUG Placebo
- DRUG Fulranumab 1 mg
- DRUG Fulranumab 3 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-07-10 |
| Est. Completion | 2016-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02289716
The ClinicalTrials.gov registry entry for NCT02289716 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02289716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02289716 about?
NCT02289716 is a clinical study titled "Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003". The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not adequately controlled by current pain therapy.
What is the current status of trial NCT02289716?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2015-07-10. Estimated completion is 2016-10-10.
What interventions are being tested in trial NCT02289716?
The interventions under investigation include: Placebo (DRUG), Fulranumab 1 mg (DRUG), Fulranumab 3 mg (DRUG).
Who is sponsoring clinical trial NCT02289716?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.